Yorkville Advisors Global’s FibroBiologics FBLG Stock Holding History

Yorkville Advisors Global’s Portfolio FBLG Stock Details FBLG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-25,489	Closed	-$278K	–	39
2025 Q3	$278K	Sell	25,489 -16,716	-40%	-$200K	0.11%	21
2025 Q2	$525K	Buy	+42,205	New	+$761K	0.15%	7

Other funds holding FBLG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CFP

Cascade Financial Partners San Diego, California $1.15B AUM 33.6% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

ANTB

AMG National Trust Bank Greenwood Village, Colorado $4.88B AUM 24.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Yorkville Advisors Global's FBLG Position: Q4 2025 in Review

Yorkville Advisors Global sold out of FibroBiologics (FBLG) in Q4 2025, closing a stake of 25,489 shares — an estimated $278K sold.

Yorkville Advisors Global first reported a position in FBLG in Q2 2025 and held it in 2 quarters. The position peaked at $525K in Q2 2025. 45 funds tracked by Wall St. Rank hold FBLG as of Q4 2025.

Yorkville Advisors Global reported no remaining FibroBiologics position as of Q4 2025 after selling out during the quarter.
Yorkville Advisors Global sold 25,489 FibroBiologics shares in Q4 2025, an estimated $278K.
Yorkville Advisors Global first reported a position in FibroBiologics in Q2 2025 and held it in 2 quarters.
Yorkville Advisors Global's FibroBiologics position peaked at $525K in Q2 2025.
45 funds tracked by Wall St. Rank held FibroBiologics as of Q4 2025.

Based on Yorkville Advisors Global's 13F filing for Q4 2025, filed 10 Feb 2026.